David González de Castro

Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial

Ian Chau, David Cunningham, David González de Castro et al. · The Lancet Oncology · 2013 · 728 citations

Medicine, Oncology, Pharmacology +13

Mismatch Repair Deficiency, Microsatellite Instability, and Survival

Elizabeth Smyth, Andrew Wotherspoon, Clare Peckitt et al. · JAMA Oncology · 2017 · 521 citations · Full text

Life Sciences, Molecular Genetics, Oncology +17

Multicenter Randomized Phase II Clinical Trial Comparing Neoadjuvant Oxaliplatin, Capecitabine, and Preoperative Radiotherapy With or Without Cetuximab Followed by Total Mesorectal Excision in Patients With High-Risk Rectal Cancer (EXPERT-C)

Alice Dewdney, David Cunningham, Josep Tabernero et al. · Journal of Clinical Oncology · 2012 · 390 citations · Full text

Medicine, Oncology, Surgery +17

Mutational Status of the <i>TP53</i> Gene As a Predictor of Response and Survival in Patients With Chronic Lymphocytic Leukemia: Results From the LRF CLL4 Trial

David González de Castro, Pilar Martı́nez, Rachel Wade et al. · Journal of Clinical Oncology · 2011 · 267 citations

Medicine, Molecular Genetics, Oncology +11

Refining the Diagnosis and EGFR Status of Non-small Cell Lung Carcinoma in Biopsy and Cytologic Material, Using a Panel of Mucin Staining, TTF-1, Cytokeratin 5/6, and P63, and EGFR Mutation Analysis

Andrew G. Nicholson, David González de Castro, Pallav L. Shah et al. · Journal of Thoracic Oncology · 2010 · 213 citations · Full text

Medicine, Oncology, Pathology +15